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Objective: Human papillomavirus (HPV) vaccine uptake in many countries has been sub-optimal. We
examine several issues associated with non-vaccination that have received particular attention, including
fears about sexual risk compensation, concerns about vaccine safety, inadequate vaccination recommendations
by health care providers (HCPs), and distrust due to the perceived “newness” of HPV vaccines.
Methods: Selective review of behavioral and social science literature on HPV vaccine attitudes and uptake.
Results: There is no evidence of post-vaccination sexual risk compensation, HPV vaccines are quite safe, andthey can no longer be considered “new”. Nonetheless, research ﬁndings point to these issues and, most important-
ly, to the failure of HCPs to adequately recommend HPV vaccine as major drivers of non-vaccination.
Conclusion: Most fears related to HPV vaccine are more related to myth than reality. In the absence of major
health policy initiatives, such as those implemented in Canada, the U.K., and Australia, a multi-level, multi-faceted
approachwill be required to achieve high rates of HPV vaccination. It will be essential to focus on the education of
HCPs regarding indications for HPV vaccination and approaches to communicating most effectively with parents
and patients about the safety and beneﬁts of vaccination and the risks associated with non-vaccination.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.Introduction
Human papillomavirus (HPV), a highly prevalent sexually trans-
mitted infection (Dunne et al., 2007; Smith et al., 2011; Winer et al.,
2008), has potentially serious health consequences in males and
females, including anogenital and oropharyngeal cancers and genital
warts (Chaturvedi, 2010; Giuliano et al., 2010; Parkin and Bray,
2006). HPV vaccination can be a very effective way to prevent infec-
tion; however vaccine uptake has been variable and suboptimal in
most countries, with low levels of both initiation and completion of
the three-dose series (Etter et al., 2012). A considerable amount of
research has focused on identiﬁcation of factors that inﬂuence HPV vac-
cine uptake (see recent reviews by: Etter et al., 2012; Fisher, 2012;
Stupiansky et al., 2012). Some of the many factors associated with
non-vaccination are information deﬁcits and include lack of knowledge
about HPV infection and vaccination and frank misinformation that is
antagonistic to vaccine uptake (e.g., that HPV vaccine will provoke sex-
ual disinhibition or that vaccines are unsafe, ineffective, and insufﬁcient-
ly studied). Other barriers to vaccination involve motivational obstacles,nc. Open access under CC BY-NC-SA lisuch as negative attitudes about HPV vaccination (based on negative
beliefs about the outcomes of vaccination, which are often the result
of dissemination of inaccurate information from anti-vaccine groups)
and lack of social support from signiﬁcant others for vaccination (e.g.,
lack of health care provider (HCP) recommendation). Finally, logistical
obstacles to HPV vaccination include the complexities of access to
service, vaccine cost, and the requirement for multiple vaccine doses.
The intent of this paper is not to provide a comprehensive review of
behavioral science research about HPV vaccination (for recent reviews
of this literature, see, for example, Etter et al., 2012; Fisher, 2012;
Stupiansky et al., 2012). Rather, it is to provide a targeted commentary
that addresses a speciﬁc set of topics that we consider timely and
important. We therefore critically examine several of the issues and
misconceptions associated with HPV vaccine refusal/non-acceptance
that have received particular attention in the research literature and
popular media, including fears about risk compensation, concerns
about vaccine safety, inadequate vaccination recommendations
by HCPs, and distrust due to the perceived “newness”, as well as the
perceived “stigma” of HPV vaccines.
Risk compensation
One of the presumed concerns about HPV vaccine is the fear that
adolescents will respond to vaccination with sexual risk compensa-
tion (also referred to as sexual disinhibition), initiating sexual activity
at a younger age and/or reducing self-protective sexual behaviors.cense.
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media (Abdelmutti and Hoffman-Goetz, 2010; Forster et al., 2010)
and parental concern about disinhibition has been found to be associ-
ated with lower HPV vaccine acceptability (Zimet et al., 2008).
However, post-licensure research has generally shown that fear
about sexual disinhibition is not frequently endorsed by parents as a
major reason for non-vaccination (Ogilvie et al., 2010; Schuler et al.,
2011). In addition, several research studies have now been published
that strongly suggest that risk compensation is not a post-vaccination
problem (Bednarczyk et al., 2012; Cummings et al., 2012; Forster et
al., 2012; Kahn et al., 2012; Liddon et al., 2012b; Mullins et al.,
2012). One U.S. national cross-sectional study of 15–24 year old
females found no evidence of sexual disinhibition in vaccinated
compared to unvaccinated females (Liddon et al., 2012b). Another
cross-sectional study of 13–21 year old females who had just re-
ceived their ﬁrst dose of vaccine found that a large majority of partic-
ipants recognized the need for ongoing safer sexual behaviors
post-vaccination (Mullins et al., 2012). Similar ﬁndings were reported
in a study of 16–23 year old HIV-infected young women (Kahn et al.,
2012). A longitudinal study in the U.K. surveyed 16–17 year old girls
before and after HPV vaccine was offered (Forster et al., 2012). After
adjusting for baseline characteristics, participants who received
vaccine were not more likely to have initiated sexual intercourse at
the time of the follow-up survey. Furthermore, among those who
were sexually active, vaccination status was not predictive of frequency
of condom use. Moreover, in a study of 14–17 year old girls that
involved a comparison of 75 who were recruited after HPV vaccine
licensure to 150 who were recruited prior to licensure, no difference
was found in the rates of gonorrhea, chlamydia, and trichomonas infec-
tions (Cummings et al., 2012). The only difference in self-reported
sexual behaviors was that the pre-licensure group had more instances
of unprotected sexual intercourse than the post-licensure group, the
opposite of what would have been predicted by risk-compensation
theory. Finally, a very recent analysis of a large managed care data
base found that vaccinated girls did not have higher subsequent scores
on a sexual-risk composite measure that included rates of pregnancy,
pregnancy testing, sexually transmitted infection testing or diagnosis,
and contraceptive counseling (Bednarczyk et al., 2012). The ﬁndings
presented above may reassure parents and providers who are reluctant
to vaccinate due to concerns about risk compensation. However, as
noted by Stupiansky and Zimet (2013), “… it is important to remember
that risk compensation (real or imagined) is not a rationale for
withholding vaccine. Instead, it is a rationale for ensuring adequate
education both pre- and post-vaccination” (p. 262).
Safety issues
Underlying some parental HPV vaccine concerns (e.g., feeling that
HPV vaccine is too new) are questions about vaccine safety (Fisher,
2012; Krawczyk et al., unpublished results). Fear-inducing news
stories may have contributed to these concerns as they sometimes
have misreported Vaccine Adverse Event Reporting System data,
incorrectly suggesting that HPV vaccination has often led to severe
adverse health effects, including death (see, for example the August,
2007 edition of Maclean's magazine in Canada; Gulli, 2007). Numer-
ous large-scale studies on HPV vaccine safety have been published
and show little or no evidence of severe side-effects associated with
vaccination (Agorastos et al., 2009; Chao et al., 2012; Gee et al.,
2011; Klein et al., 2012; Lu et al., 2011). The most frequently reported
side-effects are similar to those reported with other vaccines and are
transient events, such as mild pain and bruising at the injection site,
faintness, and syncope (Naleway et al., 2012). It is important to
highlight that a reported adverse event after vaccination does not
automatically mean that it was caused by the vaccine. A major
challenge, however, is how to effectively communicate to parents
the evidence that HPV vaccine is quite safe. As noted following, anadditional challenge involves communicating the very substantial
risks of non-vaccination, in the context of generalized, relatively
early, sexual debut, delayed marriage, serial monogamy, and the
accumulation of risk of HPV infection over time.
Communication of safety data
Development of effective strategies for clearly and accurately
communicating information about risk of vaccines has been an
enduring focus of vaccine researchers (Ball et al., 1998; Betsch and
Sachse, 2013; Davis et al., 2001; Ofﬁt and Cofﬁn, 2003). Best practices
in this regard may rest on the nature of the vaccine (routine versus
elective), the controversies that may surround the vaccine (e.g.,
MMR and autism, HPV and risk compensation), and, importantly,
whether parents or patients harbor ongoing concerns about HPV
vaccine safety, actively ask about vaccine safety, or have no concerns
in this area. Suggestions for communication about HPV vaccine safety
include asking patients whether they have any questions about the
vaccine and providing accurate information (including credible
websites) that can address concerns about safety. Further, in discus-
sions of vaccine safety, a useful approach may be to reframe non-
vaccination as an active decision, comparable to vaccination, introduc-
ing the notion that there is risk associated with not receiving HPV
vaccine. When presented side by side, the minimal risks associated
with the decision to vaccinate may be completely over-shadowed by
the health risks associatedwith the decision to not vaccinate, potential-
ly aiding parents and young adults in making decisions about HPV
vaccination. Communication concerning the high prevalence of HPV
and the high likelihood of acquisition of the virus shortly after sexual
debut also may be instrumental in conveying the risk of inaction as a
counterpoint to discussion of risk of vaccination. As a note of caution,
however, acknowledging the known minor risks associated with HPV
vaccination (e.g., pain at the injection site, syncope, dizziness, mild
fever) is very important. Recent research suggests that communicating
that vaccination entails no risk may, paradoxically, lead patients to
view vaccines as more risky (Betsch and Sachse, 2013).
HCPs' inﬂuence on HPV vaccine uptake
Particularly in the U.S., where HPV vaccination typically occurs in
medical settings, the recommendation from a HCP plays a central
role in the decision to receive HPV vaccine (Brewer et al., 2011;
Guerry et al., 2011). A recent study of Canadian undergraduates
showed similar results (Krawczyk et al., 2012). Conversely, among
those who have not received HPV vaccine, the lack of HCP recommen-
dation has been identiﬁed as a major reason for non-vaccination
(Liddon et al., 2012a; Zimet et al., 2010). While HCPs generally em-
brace their important role in recommending the HPV vaccine, these
recommendations may nevertheless be unevenly carried out due to
such issues as time constraints, patient age, availability of insurance
or other coverage, safety and/or efﬁcacy concerns, and discussion of
sexuality and information needs (Vadaparampil et al., 2011). Vaccine
risk communication, in general, is a challenge to HCPs (Evans and
Bostrom, 2002). Some providers feel that extensive discussion of
risks and beneﬁts of vaccines (including sexuality issues related to
HPV transmission in particular) might alarm rather than reassure
and may take up too much time. Many HCPs report feeling uncom-
fortable engaging in discussions regarding sexuality with their
adolescent patients (Esposito et al., 2007; Schnatz et al., 2010),
while others feel more comfortable discussing sexuality primarily
with older adolescents or with males over females (Kahn et al.,
2005; Ko et al., 2010).
One potential strategy for overcoming the problems associated
with reliance on HCP recommendations would be to establish alter-
nate venues for vaccination, such as schools or pharmacies. The
success of school-based HPV vaccination policies, for example, is
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the U.K., and Canada (Franceschi, 2010; Garland et al., 2011;
Shearer, 2011). Another policy-based approach would be for insur-
ance companies to establish practice guidelines with high rates of
HPV vaccination identiﬁed as a benchmark for successful provision
of health care. Still another strategy for overcoming reluctance of
HCPs to discuss sexuality with patients would be to frame HPV vacci-
nation as routine, and/or to frame it as a cancer prevention vaccine.
Another set of strategies involves giving HCPs the necessary tools
to more effectively implement HPV vaccination (for some suggestions
regarding vaccinations in general, see: Leask et al., 2012; Sturm et al.,
2010). HCPs must be well-informed about current guidelines and
safety information in order to communicate accurately with parents
and adolescents (Bynum et al., 2011). Schnatz et al. (2010) found
that providers' unwillingness to discuss sexual matters with their
patients was correlated with poorer HPV knowledge. The challenge,
then, is how to educate HCPs so that they can educate their patients.
Bynum et al. (2011) emphasized the importance of professional
organizations and web-based resources in this regard. It is particular-
ly important for providers to be familiar with credible websites, as
parents of adolescents increasingly use the internet as a source for
information about HPV vaccination (Ekos Research Associates, Inc.,
2011; McRee et al., 2012b).
Promising communication strategies that can be implemented in
clinical settings include messaging to promote HPV vaccination (Cox
et al., 2010; Hopfer, 2012) and the use of text-messaging reminders
to increase returns for second and third doses of vaccine (Kharbanda
et al., 2011).
Additional challenges
In addition to the issues which have been discussed above, there
are other areas of research which both support the need for early
vaccination and alleviate some potential concerns that parents may
have when vaccinating their children against HPV. Studies that have
examined the dyadic process of vaccine decision-making between
parents and adolescents have identiﬁed beneﬁts that result from the
process itself as well as the communications surrounding HPV
vaccine. Many researchers have concluded that communication about
HPV vaccine by parents with young adolescents is an opportunity to
discuss sexual health topics which can build positive sexual health
values (Askelson et al., 2011; Brabin et al., 2009; Gamble et al., 2010;
Grifﬁoen et al., 2012; McRee et al., 2012a; Roberts et al., 2010). Addi-
tionally, there is growing empirical evidence that HPV vaccine
decision-making represents an early opportunity for adolescents to
actively participate in their own clinical health care (Alexander et al.,
2012; Brabin et al., 2009). By recognizing the HPV decision-making
process as an opportunity to instill sound health care practices in
adolescents, both clinicians and parents should embrace this unique
opportunity instead of avoiding it.
There is also strong immunologic support for early vaccination of
adolescents, as the vaccine is most effective when given prior to
sexual initiation (Villa et al., 2005) and results in a stronger immune re-
sponse in younger versus older adolescents (Dobson et al., 2013). There
is evidence, as well, that HPV vaccine induces robust immune memory
(Olsson et al., 2007) and that sufﬁcient antibody levels may last for at
least 12 years and perhaps much longer in most vaccinated individuals
(Fraser et al., 2007). Evidence has also suggested that, if needed, an ad-
ditional dose of vaccine administered years after the initial series may
boost the sustained effectiveness of vaccination (Olsson et al., 2007).
A communication challenge posed by HPV vaccination is that while
both vaccines are very efﬁcacious, they do not protect against all
types of HPV responsible for cervical and other anogenital cancers.
This kind of complexity (high efﬁcacy against vaccine types, but more
modest efﬁcacywhen the whole range of oncogenic HPV is considered)
may be difﬁcult to communicate in a health care setting and difﬁcultfor parents to understand. Visual aids, such as the use of charts and
graphs, may help to most effectively deliver this kind of information
(Chua et al., 2006). In the context of such communication, the need
for sexually active females who have been vaccinated to nonetheless
have periodic cervical cancer screening must remain an emphasis.
Although the strong evidence for efﬁcacy and safety of HPV
vaccine dispels many concerns that have been associated with a
new vaccine, it is also important to note that HPV vaccine has been
licensed in the U.S. and Canada since 2006 and in Australia since
2007 (Centers for Disease Control and Prevention, 2007; Garland
and Smith, 2010; National Advisory Committee on Immunization,
2012). Clinicians who are inﬂuential in vaccine uptake, therefore,
should no longer consider this vaccine new.
Content analysis studies about the media's representation of the
HPV vaccine demonstrate that the tone associated with the vaccine is
inconsistent, ranging from negative to neutral to positive (Briones
et al., 2012; Habel et al., 2009; Keelan et al., 2010). Unfortunately, it
is often the unrealistic, negative vaccine fears that become salient to
the public, which then tends to sensationalize potential side effects of
vaccination. These rumors then ﬁlter down to adolescents and become
further exaggerated (Brabin et al., 2009). In order to overcome this
type of misinformation, clinicians and public health ofﬁcials need to
advocate for more accurate vaccine information and evidence-based
media coverage (Cooper et al., 2008). Further, using social media
tools (e.g. Facebook, Twitter) is another key strategy to disseminate
accurate information and dispel some of misinformation that is
spread by the anti-vaccine movement (Betsch et al., 2012; Keelan
et al., 2010).Conclusions
Accumulating evidence suggests that many of the social/behavioral
concerns associated with HPV vaccine that have sparked resistance
among patients and providers (and have been the focus of media
reports) have little or no basis in reality. Several studies have been pub-
lished indicating that risk compensation after HPV vaccination is not a
signiﬁcant issue. Similarly, an increasing number of studies show that
HPV vaccine is quite safe, with little or no evidence of severe adverse
effects. While safety must continue to be closely monitored, the ﬁnd-
ings to date should be reassuring to providers, parents, young adults,
and adolescents. Although it is certainly true that parents have the
right to refuse vaccination, the “safety” of non-vaccination can be
questioned and the risks of non-vaccination can honestly be discussed.
Although Pap testing has reduced the incidence of cervical cancer,
particularly in industrialized nations, it is an imperfect approach to
prevention with only moderate sensitivity, and cervical cancer rates
remain unacceptably high. Furthermore, Pap testing cannot prevent
genital warts and anal cancers. HPV vaccine can no longer be consid-
ered a “new” vaccine, as one of the vaccines has been licensed in the
U.S./Canada for over six years and was carefully evaluated via extensive
clinical trials for many years pre-licensure.
The major challenge, then, is how to most effectively communi-
cate this information to parents, young adults, adolescents, and
HCPs so that higher HPV vaccination rates can be achieved. In the ab-
sence of major HPV vaccination health policy initiatives, such as those
implemented in Canada, the U.K., and Australia, a multi-level, multi-
faceted approach will be required. HCP recommendation is among
the most important determinants of HPV vaccination. It is essential,
therefore, to focus on the education of HCPs regarding indications
for HPV vaccination and approaches to communicating most effec-
tively with parents and patients about the safety and beneﬁts of
vaccination and the risks associated with non-vaccination. Such edu-
cational interventions should be based on established theoretical
principles, such as social cognitive theory or diffusion theory
(Bandura, 2001; Rogers, 2004), and should be empirically evaluated.
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